Rocket PharmaceuticalsRCKT
About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Employees: 299
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
152% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 23
113% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 45
19% more funds holding
Funds holding: 189 [Q3] → 224 (+35) [Q4]
1.41% more ownership
Funds ownership: 101.68% [Q3] → 103.1% (+1.41%) [Q4]
9% less call options, than puts
Call options by funds: $2.09M | Put options by funds: $2.28M
19% less capital invested
Capital invested by funds: $1.71B [Q3] → $1.38B (-$328M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Needham Gil Blum 13% 1-year accuracy 20 / 157 met price target | 503%upside $42 | Buy Reiterated | 9 Apr 2025 |
BMO Capital Kostas Biliouris 6% 1-year accuracy 1 / 17 met price target | 617%upside $50 | Outperform Initiated | 12 Mar 2025 |
Scotiabank Greg Harrison 24% 1-year accuracy 10 / 41 met price target | 646%upside $52 | Sector Outperform Maintained | 3 Mar 2025 |
Goldman Sachs Richard Law 50% 1-year accuracy 4 / 8 met price target | 115%upside $15 | Neutral Maintained | 3 Mar 2025 |
Canaccord Genuity Whitney Ijem 25% 1-year accuracy 11 / 44 met price target | 417%upside $36 | Buy Maintained | 3 Mar 2025 |
Financial journalist opinion









